Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease marked by bone and cartilage destruction. Current biologic therapies are beneficial in only a portion of patients; hence small molecules targeting key pathogenic signaling cascades represent alternative therapeutic strategies. Here we show that c-Jun N-terminal kinase (JNK) 1, but not JNK2, is critical for joint swelling and destruction in a serum transfer model of arthritis. The proinflammatory function of JNK1 requires bone marrow-derived cells, particularly mast cells. Without JNK1, mast cells fail to degranulate efficiently and release less IL-1β after stimulation via Fcγ receptors (FcyRs). Pharmacologic JNK inhibition effectively prevents arthritis onset and abrogates joint swelling in established disease. Hence, JNK1 controls mast cell degranulation and FcγR-triggered IL-1β production, in addition to regulating cytokine and matrix metalloproteinase biosynthesis, and is an attractive therapeutic target in inflammatory arthritis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 22122-22127 |
| Number of pages | 6 |
| Journal | Proceedings of the National Academy of Sciences of the United States of America |
| Volume | 107 |
| Issue number | 51 |
| DOIs | |
| State | Published - Dec 21 2010 |
Fingerprint
Keywords
- Fcγ receptor
- Immune complex
ASJC Scopus subject areas
- General
Cite this
JNK1 controls mast cell degranulation and IL-1β production in inflammatory arthritis. / Guma, Monica; Kashiwakura, Jun Ichi; Crain, Brian; Kawakami, Yuko; Beutler, Bruce; Firestein, Gary S.; Kawakami, Toshiaki; Karin, Michael; Corr, Maripat.
In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, No. 51, 21.12.2010, p. 22122-22127.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - JNK1 controls mast cell degranulation and IL-1β production in inflammatory arthritis
AU - Guma, Monica
AU - Kashiwakura, Jun Ichi
AU - Crain, Brian
AU - Kawakami, Yuko
AU - Beutler, Bruce
AU - Firestein, Gary S.
AU - Kawakami, Toshiaki
AU - Karin, Michael
AU - Corr, Maripat
PY - 2010/12/21
Y1 - 2010/12/21
N2 - Rheumatoid arthritis (RA) is a chronic inflammatory disease marked by bone and cartilage destruction. Current biologic therapies are beneficial in only a portion of patients; hence small molecules targeting key pathogenic signaling cascades represent alternative therapeutic strategies. Here we show that c-Jun N-terminal kinase (JNK) 1, but not JNK2, is critical for joint swelling and destruction in a serum transfer model of arthritis. The proinflammatory function of JNK1 requires bone marrow-derived cells, particularly mast cells. Without JNK1, mast cells fail to degranulate efficiently and release less IL-1β after stimulation via Fcγ receptors (FcyRs). Pharmacologic JNK inhibition effectively prevents arthritis onset and abrogates joint swelling in established disease. Hence, JNK1 controls mast cell degranulation and FcγR-triggered IL-1β production, in addition to regulating cytokine and matrix metalloproteinase biosynthesis, and is an attractive therapeutic target in inflammatory arthritis.
AB - Rheumatoid arthritis (RA) is a chronic inflammatory disease marked by bone and cartilage destruction. Current biologic therapies are beneficial in only a portion of patients; hence small molecules targeting key pathogenic signaling cascades represent alternative therapeutic strategies. Here we show that c-Jun N-terminal kinase (JNK) 1, but not JNK2, is critical for joint swelling and destruction in a serum transfer model of arthritis. The proinflammatory function of JNK1 requires bone marrow-derived cells, particularly mast cells. Without JNK1, mast cells fail to degranulate efficiently and release less IL-1β after stimulation via Fcγ receptors (FcyRs). Pharmacologic JNK inhibition effectively prevents arthritis onset and abrogates joint swelling in established disease. Hence, JNK1 controls mast cell degranulation and FcγR-triggered IL-1β production, in addition to regulating cytokine and matrix metalloproteinase biosynthesis, and is an attractive therapeutic target in inflammatory arthritis.
KW - Fcγ receptor
KW - Immune complex
UR - http://www.scopus.com/inward/record.url?scp=78650662299&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650662299&partnerID=8YFLogxK
U2 - 10.1073/pnas.1016401107
DO - 10.1073/pnas.1016401107
M3 - Article
C2 - 21135226
AN - SCOPUS:78650662299
VL - 107
SP - 22122
EP - 22127
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
SN - 0027-8424
IS - 51
ER -